Trial Information

Summary: Multiple Myeloma Study CLBH589B2207

Novartis Oncology is conducting this clinical trial is to find out the effects, both positive and negative, of a study drug called LBH589 when administered together with bortezomib to people who have a form of bone marrow cancer called Multiple Myeloma that has not responded to prior treatments. The study drug LBH589 is being tested as part of this study and is currently not available for purchase on the market in any country.

Participants will take oral LBH589 once-a-day on Monday, Wednesday, and Friday each week. In addition, participants will receive an injection of bortezomib twice weekly for 2 weeks. Participants will be asked to come to the clinic for five visits in the first week of the study, with the frequency of visits reducing thereafter for the length of participation in the study. Each of these visits should take about 1-3 hours, but there are a few visits that may take up to 8 hours.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 27, 2008 at 1:00:35 PM